Mindcure Completes Beta Testing, Launches PsyCollage

Mind Cure Health (CSE: MCUR) has completed the beta testing phase for its proprietary bioinformatics platform. Referred to as PsyCollage, the tool has been developed to drive decision making for drug lead optimization while also assisting in the discovery of target receptors.

The completion of the beta test marks the achievement of the firms first quarter testing milestone for the technology. The platform is being developed by the company as a means of product discovery, with the development being led by Chief Scientific Officer Dr Ryan Hartwell.

The technology works by using predicative correlative statistical analytics of documented research within the field of psychedelics. The analytics is capable of dealing with biological data with large and complex data sets, with the platform evolving into a resource for discovery and analysis of target receptors, methods, and historical clinical data trial.

Cambria Gold Mines — sponsored Sponsored · Cambria Gold Mines

Following initial beta testing, the technology has lead to Mind Cure identifying a number of priority indications, including cluster headaches, neuropathic pain, traumatic brain injury and migraines.

“The PsyCollage platform was developed to help MINDCURE accelerate research and planning to identify the therapeutic potential of psychedelic compounds and inform our priority research programs. With this strategic focus, we’re reinforcing our commitment to accelerating research to solve how the world addresses pain and suffering, and substantiating our role as leaders in psychedelic science.”

Kelsey Ramsden, President & CEO

Additional use cases and commercialization scenarios for PsyCollage are currently being evaluated by the company as well, with the platform already having been deployed for product discovery and lead optimization.

Mind Cure Health last traded at $0.63 on the CSE.


FULL DISCLOSURE: Mind Cure Health is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover Mind Cure Health on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.

Video Articles

Inside a Forgotten High-Grade Gold Mine in the Yukon | Blue Jay Gold [DD-on-the-GO Ep. 10]

WHICH MINING STOCKS CAN STILL RUN? | Mining Stock Mailbag [Nov. 9-13]

Silver’s Bull Market Isn’t Over | Peter Krauth

Recommended

First Phosphate Adds UK Export Finance to Growing Export Credit Lineup With C$220 Million Letter of Interest

Epic Gold Outlines 150,700 Indicated Ounces at 2.26 G/T in Updated Benoist Resource

Related News

Mind Cure Launches Product Sales Division

Mind Cure Health (CSE: MCUR) continued its constant roll of news this week, announcing this...

Thursday, February 18, 2021, 07:19:26 AM

Mind Cure Health Appoints Rob Hill To Board Of Directors

Mind Cure Health (CSE: MCUR) this morning announced the appointment of Rob Hill to the...

Monday, February 22, 2021, 09:12:53 AM

Mind Cure Health Focuses On Research Into Psychedelics For Traumatic Brain Injury

Mind Cure Health (CSE: MCUR) as of this morning has seen the transition of one...

Wednesday, February 17, 2021, 07:27:04 AM

Mind Cure To See Nootropics Sold Across North America Via Body Energy Club

Mind Cure Health (CSE: MCUR) this morning released further plans related to the launch of...

Thursday, December 31, 2020, 09:17:25 AM

Mindcure Ends Fiscal Q1 2022 With $15.6 Million Cash & Cash Equivalents, $2.8 Million Net Loss

Mind Cure Health (CSE: MCUR) announced on Tuesday the financial results for the three months ended...

Wednesday, October 27, 2021, 10:41:00 AM